

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Frunexian
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Cadrenal Therapeutics
Deal Size : $15.0 million
Deal Type : Acquisition
Cadrenal Acquires eXIthera’s Factor XIa Inhibitors Portfolio
Details : The Acquisition enhances the Company’s pipeline by adding novel assets, including frunexian, a first-in-class, Phase 2-ready IV Factor XIa inhibitor in acute and chronic anticoagulation settings.
Product Name : EP-7041
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 15, 2025
Lead Product(s) : Frunexian
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Cadrenal Therapeutics
Deal Size : $15.0 million
Deal Type : Acquisition
